Pentax Medical
Pentax Medical, a division of Hoya Corporation, is a leading provider of innovative medical imaging solutions, headquartered in Japan. Established in 1919, the company has a rich history of advancements in endoscopy and minimally invasive surgical technologies, serving healthcare professionals across the globe, particularly in Europe, Asia, and North America. Specialising in endoscopic equipment, Pentax Medical offers a range of products, including high-definition endoscopes and imaging systems that enhance diagnostic accuracy and patient outcomes. Their commitment to quality and innovation has positioned them as a trusted partner in the medical community, with notable achievements in developing user-friendly devices that prioritise patient safety and comfort. With a strong market presence, Pentax Medical continues to lead the way in transforming healthcare through cutting-edge technology.
DitchCarbon Score
How does Pentax Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pentax Medical's score of 41 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pentax Medical's reported carbon emissions
In 2025, Pentax Medical reported total carbon emissions of approximately 788,000 kg CO2e. This figure includes 52,000 kg CO2e from Scope 1 emissions, 29,000 kg CO2e from Scope 2 emissions, and a significant 707,000 kg CO2e from Scope 3 emissions. Comparatively, in 2023, the company’s total emissions were about 866,000 kg CO2e, with Scope 1 and Scope 2 emissions remaining consistent at 52,000 kg CO2e and 29,000 kg CO2e, respectively. The Scope 3 emissions for that year were approximately 785,000 kg CO2e. In 2022, total emissions were slightly higher at around 886,000 kg CO2e, with similar Scope 1 and Scope 2 figures and Scope 3 emissions of about 804,000 kg CO2e. Despite these figures, Pentax Medical has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company is actively working towards sustainability, but further details on their commitments or strategies for reducing emissions are not available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2025 | |
|---|---|---|---|
| Scope 1 | 52,000 | 00,000 | 00,000 |
| Scope 2 | 29,000 | 00,000 | 00,000 |
| Scope 3 | 804,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pentax Medical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
